To treat or not to treat young children with hepatitis C?––real-life experience
• This is one of the few studies that analyzed the safety and efficacy of DAAs in young children with hepatitis C in a real-life setting, which confirmed both the efficacy and tolerability of DAAs for the treatment of hepatitis C in children aged 3-6 years. • We present a new algorithm for therapeutic management in young children with hepatitis C based on individual qualification for treatment according to the child's ability and willingness to swallow medications.
Authors
- Magdalena Marczyńska (ORCID: https://orcid.org/0000-0001-5731-6346)
- Anna Dobrzeniecka (ORCID: https://orcid.org/0000-0003-1731-2329)
- Maria Pokorska‐Śpiewak (ORCID: https://orcid.org/0000-0001-7783-6904)
- Małgorzata Aniszewska (ORCID: https://orcid.org/0000-0002-6964-0706)
- Ewa Talarek (ORCID: https://orcid.org/0000-0002-3466-0782)
Institutions
- Medical University of Warsaw (PL)
- Central Clinical Hospital (PL)
Publication Details
- Journal
- European Journal of Pediatrics
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1007/s00431-025-06517-7
- Citations
- 1
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 1.32